ReviewA review of vaccine research and development: Meningococcal disease☆
Introduction
Central nervous system infections, including bacterial and viral meningitis, are major causes of morbidity and mortality. Bacterial meningitis remains a serious threat to global health, accounting for an estimated annual 500,000 cases worldwide with at least 50,000 deaths and as many cases of neurological damage [1]. It has been estimated that in developing countries such as The Gambia, 2% of all children born will die of meningitis before they reach 5 years of age [2]. Even with antimicrobial therapy and the availability of sophisticated intensive care, case fatality rates remain at 5%–10% in industrialized countries, and can reach 20% in the developing world. Between 10% and 20% of survivors develop permanent sequelae such as epilepsy, mental retardation or sensorineural deafness.
Three bacterial species, Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis, are responsible for most cases of meningitis occurring beyond the neonatal period. The incidence of S. pneumoniae is greatest in small infants and children less than 2 years old, that of H influenzae in children from 6 months to 2 years of age, and that of N. meningitidis in children, adolescents and young adults from 1 to 29 years of age. Diagnosis of the etiological agent generally rests on Gram stain and culture of cerebrospinal fluid (CSF), but rapid tests based on latex agglutination, stick chromatography immunodetection, multiplex PCR or DNA microarrays are progressively been implemented. The introduction of H. influenzae type b (Hib) conjugate vaccines in many countries for routine immunization has nearly eliminated invasive Hib disease in those countries. N. meningitidis and S. pneumoniae have therefore now become the commonest cause of bacterial meningitis in the world. Meningococcal disease is a global problem that occurs in all countries. In the few surveys done in sub-Saharan Africa, S. pneumoniae accounted for about 20%–30% of meningitis cases, whereas N. meningitidis was responsible for 60%–65% of cases. N. meningitidis moreover is the only bacterium capable of generating epidemics of meningitis. Epidemics have been described as early as 1805 in Europe and recognized for more than 100 years in sub-Saharan Africa.
All these pathogens possess a cell surface polysaccharide (CPS) capsule, which prevents activation of the complement by cell surface bacterial proteins and inhibits phagocytosis and bacterial killing, but which also can serve as the antigen of choice for the development of preventive vaccines. They also are characterized by their propensity to colonize the nasopharynx in a harmless way, from where they can invade the host and cause silent bacteraemia or overt infections, such as otitis media, pneumonia, or meningitis.
Among the elderly, pregnant and immunocompromized patients, additional pathogens can cause meningitis, such as Listeria monocytogenes, a Gram positive rod that causes infection in immunocompromized persons and pregnant women and Cryptococcus neoformans, which has become an important cause of meningitis among immunocompromized patients. Neonatal meningitis is a distinct clinical entity, frequently caused by Escherichia coli or group B streptococci. Other pathogens such as Mycobacterium tuberculosis, Treponema pallidum or Borrelia burgdorferi, the causative agent of Lyme disease, may also present as aseptic meningitis. Viruses also cause meningitis, including coxsackieviruses and echoviruses, or, less frequently, cytomegalovirus, herpes simplex virus and HIV.
This review will focus on vaccines against meningococcal disease due to Neisseria meningitidis, which can cause severe meningitis and septicemia and which is unique among cases of meningitis for its ability to cause large scale epidemics [3], [4]. The development of new vaccines against Hib and S. pneumoniae was recently reviewed [5], including the multivalent pneumococcal glycoconjugate vaccines from Wyeth [6], [7], [8] that are under development [9].
Section snippets
Disease burden
N. meningitidis is a common inhabitant of the mucosal membranes of the human nasopharynx, where it usually lies as a harmless commensal. Up to 5%–10% of a population may be asymptomatic carriers in non-epidemic settings. Most cases are acquired by person-to-person contact through aerosol droplets or contacts with respiratory secretions from asymptomatic carriers. A small minority of those who become infected eventually will develop an acute inflammation of the meninges. Among the 13 distinct N
Bacteriology
N. meningitidis is a gram-negative encapsulated diplococcus, which comprizes at least 13 different serogroups defined on the basis of the immunochemistry of their capsular PS, with only serogroups A, B, C, Y and W135 being confirmed pathogens. The bacterium readily colonizes the nasopharynx of humans and has no other known environmental niche. About 10% of the human population is estimated to be carriers. Meningococci are further classified into serotypes and subtypes on the basis of the
Vaccines
Groups A, C, Y and W135 infections can be prevented by vaccines based on high molecular weight CPS [24]. These vaccines unfortunately do not induce T-cell-dependent immunity, are poorly effective in young children and infants and do not elicit long-term immune memory. The chemical conjugation of CPS to protein carrier molecules ensures that a T-cell-dependent immune response is induced [25]. This approach, however, does not hold for group B meningococci, for which the prospect of developing a
Concluding remarks
Global elimination of bacterial meningitis may well be an achievable target when potent and affordable vaccines against meningococcus ACYW and B become available within the next decade. The meningococcus group A glycoconjugate vaccine developed by MVP is expected to be made available to countries in the meningitis belt by 2008–2009. The issue of moving from a monovalent conjugate MenA to a bivalent conjugate MenA/W135 vaccine in these countries has been widely discussed. At this time, in view
Acknowledgement
The efficient editorial help of Olga Assossou is gratefully acknowledged.
References (82)
- et al.
A review of vaccine research and development: human acute respiratory infections
Vaccine
(2005) - et al.
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial
Lancet
(2003) - et al.
New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery
Vaccine
(2005) - et al.
Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study
Lancet
(2005) Reverse vaccinology, a genome-based approach to vaccine development
Vaccine
(2001)- et al.
Vaccine prevention of meningococcal disease, coming soon?
Vaccine
(2001) - et al.
Development of vaccines against meningococcal disease
Lancet
(2002) - et al.
Conjugation of meningococcal lipooligosaccharides through their lipid A terminus conserves their inner epitopes and results in conjugate vaccines having improved immunological properties
Carbohydr Res
(2003) - et al.
Meningococcal polysaccharide-protein conjugate vaccines
Lancet Infect Dis
(2005) - et al.
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
Vaccine
(2001)
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
Lancet
Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease
Vaccine
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making
Vaccine
Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger
Vaccine
Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
Lancet
Meningococcal molecular mimicry and the search for an ideal vaccine
Trans R Soc Trop Med Hyg
Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers
Vaccine
Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant
Vaccine
Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
Vaccine
Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants
Vaccine
Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis
Vaccine
Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals
Vaccine
Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B
Vaccine
Identification of novel antigens that protect against systemic meningococcal infection
Vaccine
Conjugated vaccines
Therapie
Vaccines based on the cell surface carbohydrates of pathogenic bacteria
An Acad Bras Cienc
Meningococcal disease
N Engl J Med
Meningococcal vaccines
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
Pediatr Infect Dis J
Postlicensure evaluation of the effectiveness of seven-valent pneumococcal conjugate vaccine
Pediatr Infect Dis J
Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants
Pediatr Infect Dis J
Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study
BMJ
Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex
J Infect Dis
Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China
Infect Immun
Increasing incidence of meningococcal disease in Spain associated with a new variant of serogroup C
Eur J Clin Microbiol Infect Dis
Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales
Commun Dis Rep CDR Rev
The changing epidemiology of meningococcal disease in the United States
J Infect Dis
New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4
J Infect Dis
Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms
Proc Natl Acad Sci USA
Population genetics and molecular epidemiology of Neisseria meningitidis
Apmis
Cited by (169)
Soil-transmitted helminthic vaccines: Where are we now?
2023, Acta TropicaRecommended/required travel vaccines
2018, Travel MedicineNovel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
2017, Synthetic and Systems BiotechnologyCitation Excerpt :To date, reductive amination has been the most broadly used method to successfully conjugate PSs to proteins for the purpose of manufacturing conjugate vaccines. PS-protein conjugates for H. influenzae type b [22], N. meningitidis serotypes A, C, W, Y136 [23,24], and 13 serotypes of S. pneumoniae [25], have all been approved for worldwide use to date [20]. With respect to PCV development, though many other PnPS conjugation chemistries have been used experimentally, only reductive amination (Prevnar®13) and CDAP (Synflorix®) processes have resulted in conjugated antigens that are effectively immunogenic and sufficiently stable to achieve regulatory approval to date, as well as adequately scalable to enable the high volume manufacturing that is required to significantly impact global health.
- ☆
The authors alone are responsible for the views expressed in this publication, which does not necessarily reflect the views of the World Health Organization.
- 1
Tel: +41 22 791 35 91.